# The Switch Study: The Role of Lamivudine/Emtricitabine (3TC/FTC) in Antiretroviral Regimens

> **NCT00152061** · NA · COMPLETED · sponsor: **Stanford University** · enrollment: 40 (—)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** 3TC and FTC

## Key facts

- **NCT ID:** NCT00152061
- **Lead sponsor:** Stanford University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-01
- **Primary completion:** —
- **Final completion:** 2005-08
- **Target enrollment:** 40 (—)
- **Last updated:** 2013-06-19

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00152061

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00152061, "The Switch Study: The Role of Lamivudine/Emtricitabine (3TC/FTC) in Antiretroviral Regimens". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00152061. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*